Histocell. Regenerative Medicine

Histocell. Regenerative Medicine

Histocell is a clinical-stage biopharmaceutical company dedicated to developing advanced therapy medicinal products, medical devices, and dermocosmetics for regenerative medicine, with a primary focus on controlling oxidative stress to improve people's quality of life. Established in 2004 and headquartered in Spain, the company operates from the Bizkaia Science and Technology Park, boasting a 65 m2 GMP certified manufacturing room, laboratories for quality control and R&D, and a 2000 m2 medical device manufacturing plant. Committed to meeting the highest quality standards, Histocell holds GMP and ISO 9001/2000 certifications.

The company's diverse pipeline encompasses medical devices such as Reoxcare, Vexoderm for Natural Wound Healing, Histoessence, Wharton Gel Complex, Neofibrin for Dermatologic Tissue Regeneration, along with Cell Therapy programs based on adipose-derived mesenchymal stem cells (AMSC) for Bone Regeneration and on HC016 cellular product (proprietary technology) for Acute Spinal Cord Injury and Lung disease. Furthermore, as an authorized ATMP manufacturing laboratory, Histocell provides Contract Manufacturing Services for both GMP and GMP-like manufacturing of cell therapy products.

The latest investment of €50.00K was a grant investment received on 01 February 2017 from EASME - EU Executive Agency for SMEs.

Overall, Histocell's innovative approach and ongoing development efforts in regenerative medicine make it a compelling player in the Biotechnology and Health Care sectors, positioned to drive significant impact in the field of regenerative medicine.